GameStop Corp. vs Zoetis Inc — how do they compare? GameStop Corp. trades at $26.57 (market cap $12.75B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.4× GameStop Corp.'s market cap, and Zoetis Inc pays a 2.9% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Zoetis Inc for 70 Days on average.
| GME | ZTS | |
|---|---|---|
Market Cap | $12.75B | $30.20B |
Volume | 13,026,993 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $147.53 |
52-Week Low | $17.87 | $69.09 |
Typical Hold Time | 62 Days | 70 Days |
Enterprise Value | $12.03B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
GME trades at $26.56, up 8.06% over 24 hours, with a bullish technical signal supported by moving averages. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, while revenue declined to $3.82 billion. Strong insider buying by CEO Ryan Cohen and directors has fueled positive sentiment, though analyst consensus remains cautious with a majority hold rating.
The outlook for GME hinges on execution of its strategic pivot to high-margin collectibles and leveraging its $4.77 billion cash position. Key risks include revenue volatility, competitive pressures, and dependence on insider confidence. Upside potential exists if earnings growth sustains, but investors face uncertainty from inconsistent profitability and high valuation multiples relative to historical performance.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →